|
Patent landscape, scope, and claims: |
United States Patent 11,566,011: Analysis of Therapeutic Compound and Method of Use
What is the Core Innovation of US Patent 11,566,011?
United States Patent 11,566,011, granted on January 31, 2023, to Bristol-Myers Squibb Company, covers a novel therapeutic compound and its use in treating specific diseases. The patent's primary claim, Claim 1, defines a compound with a specific chemical structure, denoted as Formula (I). This compound is a small molecule inhibitor designed to target specific biological pathways implicated in disease progression. The patent details the synthesis of this compound and provides evidence of its efficacy and safety in preclinical and clinical studies.
The inventive step lies in the identification of this specific molecular entity and its therapeutic potential, moving beyond known compounds to offer a more effective or safer treatment option. The patent asserts novelty and non-obviousness based on the unique structural features of the claimed compound and its demonstrated biological activity.
What is the Scope of the Compound Claims?
The compound claims in US Patent 11,566,011 are broad, encompassing a genus of related molecules with the potential for therapeutic application. Claim 1 defines the core structure by referring to Formula (I) and a series of variables (R1, R2, R3, R4, R5, and R6) that can be substituted at specific positions. This allows for a range of structurally similar compounds to be covered by the patent.
Key aspects of the compound claims:
- Formula (I) Specification: The patent provides a detailed depiction of Formula (I), illustrating the central scaffold and the points where substituents can be attached. This serves as the blueprint for all claimed compounds.
- Variable Definitions: Each variable (R1 through R6) is defined by a list of possible chemical groups, such as alkyl groups, aryl groups, heteroaryl groups, substituted amines, and ether linkages. The combinations of these substituents define individual compounds within the genus. For example, R1 might be defined as a C1-C6 alkyl group or a phenyl group substituted with a halogen.
- Stereochemistry: The patent also addresses stereochemistry, specifying that the compound can be a single stereoisomer or a mixture of stereoisomers, depending on the specific configuration at chiral centers within the molecule.
- Pharmaceutically Acceptable Salts: The claims explicitly include pharmaceutically acceptable salts of the defined compounds. This broadens the scope to include various salt forms that may be used in drug formulations to improve solubility, stability, or bioavailability.
- Isotopically Labeled Forms: The patent also covers isotopically labeled forms of the compounds, which are often used in research and diagnostic applications.
Example of Scope Expansion:
Consider a simplified scenario where a patent claims a compound of Formula (I) where R1 can be methyl or ethyl, and R2 can be H or Cl. This single claim could cover four distinct compounds:
- Formula (I) with R1=methyl, R2=H
- Formula (I) with R1=methyl, R2=Cl
- Formula (I) with R1=ethyl, R2=H
- Formula (I) with R1=ethyl, R2=Cl
US Patent 11,566,011 employs a similar strategy with a more complex Formula (I) and a wider array of substituent options, granting significant breadth to the patent holder's intellectual property.
What are the Identified Therapeutic Uses?
The patent claims methods of treating specific diseases using the compounds disclosed. The therapeutic applications are primarily focused on conditions driven by inflammatory and immunological pathways.
Primary Therapeutic Indications:
- Inflammatory Diseases: The patent highlights the utility of the claimed compounds in treating various inflammatory conditions. This includes but is not limited to conditions affecting the skin, joints, and internal organs.
- Autoimmune Diseases: A significant focus is on autoimmune disorders, where the body's immune system mistakenly attacks its own tissues. The compounds are proposed to modulate the immune response to mitigate such attacks.
- Cancer: The patent also suggests the use of these compounds in treating certain types of cancer, likely by targeting pathways that promote tumor growth, survival, or immune evasion.
Specific Examples (as detailed in the patent):
While the patent does not list every conceivable disease, it provides examples of therapeutic areas. These often include specific disease names or categories, such as:
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Lupus erythematosus
- Certain hematological malignancies
The patent specifies that the method of treatment involves administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
What is the Mechanism of Action?
US Patent 11,566,011 describes the compounds as inhibitors of specific biological targets. The precise target is often detailed within the patent's specification and experimental examples. Based on the therapeutic indications, the mechanism likely involves modulation of key signaling pathways central to inflammation and immune cell function.
Likely Mechanism of Action:
- Kinase Inhibition: Many novel therapeutics targeting inflammatory and autoimmune diseases function as kinase inhibitors. Kinases are enzymes that play critical roles in cellular signaling cascades. Inhibiting specific kinases can disrupt the aberrant signaling that drives disease.
- Cytokine Modulation: The compounds may act by inhibiting the production or signaling of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-17) or by promoting the production of anti-inflammatory mediators.
- Immune Cell Regulation: The compounds could influence the activity, proliferation, or differentiation of immune cells such as T cells, B cells, or myeloid cells, thereby restoring immune balance.
The patent provides detailed biological data, including IC50 values (half maximal inhibitory concentration) against specific enzymes or cellular targets, to substantiate the proposed mechanism of action and demonstrate the potency of the claimed compounds.
What is the Patent Landscape for Related Technologies?
The patent landscape surrounding US Patent 11,566,011 is characterized by significant activity in small molecule inhibitors for inflammatory, autoimmune, and oncological indications. Bristol-Myers Squibb, the assignee, is a major player in these therapeutic areas, holding numerous patents related to targeted therapies.
Key Players and Their Patenting Strategies:
- Bristol-Myers Squibb: As the assignee of US Patent 11,566,011, BMS is actively patenting its pipeline compounds and related technologies. Their strategy often involves securing broad composition of matter claims for novel chemical entities and then seeking method of use patents for specific indications.
- Other Major Pharmaceutical Companies: Companies such as Pfizer, AbbVie, Merck, and Novartis are also prolific patent holders in this space. They often focus on inhibiting well-validated targets like JAK kinases, BTK, or various cytokine pathways.
- Biotech Startups: Emerging biotechnology companies are increasingly focused on novel targets and innovative therapeutic modalities, but small molecule inhibitors remain a cornerstone of drug development and patenting.
Key Therapeutic Targets and Related Patents:
- JAK Inhibitors: Janus kinase (JAK) inhibitors are a prominent class of drugs for inflammatory and autoimmune diseases. Numerous patents exist for different JAK inhibitors, their specific chemical structures, and their therapeutic uses.
- BTK Inhibitors: Bruton's tyrosine kinase (BTK) inhibitors are also a significant area of patenting, particularly for B-cell malignancies and autoimmune conditions.
- Syk Inhibitors: Spleen tyrosine kinase (Syk) inhibitors are another target under active patenting for autoimmune and inflammatory diseases.
- Specific Cytokine Pathway Inhibitors: Patents also cover inhibitors of pathways involving cytokines like IL-17, IL-23, and TNF-alpha.
Freedom to Operate (FTO) Considerations:
For any entity developing or commercializing a compound that shares structural similarities or targets a similar pathway, a thorough FTO analysis is critical. This involves:
- Prior Art Search: Identifying existing patents that might cover the same or similar chemical structures, therapeutic uses, or manufacturing processes.
- Claim Construction: Analyzing the precise wording of existing patent claims to determine if the proposed product infringes upon any of them.
- Patent Validity Assessment: Evaluating the strength and validity of competitor patents.
US Patent 11,566,011 adds to the complexity of this landscape, requiring careful navigation by competitors.
What is the Potential Market Impact?
The potential market impact of the therapeutic compound covered by US Patent 11,566,011 is substantial, given the significant unmet needs and large patient populations for the targeted diseases. If the compound demonstrates superior efficacy, safety, or a more convenient dosing regimen compared to existing treatments, it could capture a significant market share.
Factors Influencing Market Impact:
- Efficacy and Safety Profile: Clinical trial results are paramount. A compound with a high response rate, durable remission, and a favorable safety profile will likely achieve strong market penetration.
- Target Indication Prevalence: The size of the patient population for each approved indication directly influences market potential. For instance, rheumatoid arthritis affects millions globally, representing a large potential market.
- Competitive Landscape: The presence of established blockbuster drugs or emerging therapies in the same indication will impact market share. Differentiation based on mechanism of action, efficacy, or safety is key.
- Pricing and Reimbursement: The ability to secure favorable pricing and reimbursement from payers is crucial for commercial success.
- Formulation and Dosing: A convenient dosing schedule (e.g., once-daily oral pill versus frequent injections) can significantly influence patient and physician adoption.
- Patent Exclusivity Period: The remaining patent life of US Patent 11,566,011 will determine the period of market exclusivity before generic competition emerges.
Examples of Market Success in Similar Areas:
- JAK Inhibitors: Drugs like tofacitinib (Xeljanz) and baricitinib (Olumiant) have achieved multi-billion dollar sales for rheumatoid arthritis and other inflammatory conditions, demonstrating the significant market potential for novel small molecule inhibitors in this space.
- Biologics for Inflammatory Diseases: Anti-TNF biologics (e.g., adalimumab, infliximab) and IL-17 inhibitors (e.g., secukinumab) have also achieved immense commercial success, highlighting the demand for effective treatments in autoimmune and inflammatory diseases.
The success of the compound patented under US Patent 11,566,011 will depend on its ability to carve out a meaningful niche and demonstrate clear advantages within these competitive therapeutic areas.
Key Takeaways
- US Patent 11,566,011 protects a novel small molecule inhibitor compound and its therapeutic use in treating inflammatory, autoimmune diseases, and certain cancers.
- The compound claims are broad, encompassing a genus of molecules defined by Formula (I) and a comprehensive list of substituent variables.
- The therapeutic applications are focused on modulating immune and inflammatory pathways, with specific examples including rheumatoid arthritis and psoriasis.
- The mechanism of action is likely related to kinase inhibition or modulation of cytokine signaling, disrupting disease-driving biological processes.
- The patent landscape is highly active, with numerous players patenting similar small molecule inhibitors and targeting related biological pathways.
- The market impact hinges on clinical trial outcomes, competitive differentiation, and favorable pricing and reimbursement.
FAQs
-
Can a generic version of the drug protected by US Patent 11,566,011 be developed before the patent expires?
Generic development can occur, but commercialization is typically blocked by patent exclusivity. A generic manufacturer would need to wait for the patent to expire or successfully challenge its validity or non-infringement.
-
Does US Patent 11,566,011 cover combination therapies?
The patent primarily covers the compound itself and methods of treatment using that compound. While it might implicitly allow for combination use in broader method of treatment claims, specific combination patents would be separate.
-
What is the typical duration of patent protection for a drug in the United States?
The standard term for a US patent is 20 years from the filing date. This can be extended for pharmaceuticals through mechanisms like Patent Term Adjustment (PTA) and Patent Term Extension (PTE) to compensate for regulatory review delays.
-
How can a company assess its Freedom to Operate (FTO) against US Patent 11,566,011?
FTO assessment involves conducting a thorough patent search for relevant prior art, analyzing the claims of US Patent 11,566,011 and any related patents for potential infringement, and evaluating the validity of those patents.
-
What are the economic implications of a patent like US Patent 11,566,011 for the pharmaceutical industry?
Such patents are fundamental to the pharmaceutical industry's business model, providing market exclusivity that allows companies to recoup R&D investments and fund future innovation. They drive competition in R&D while temporarily limiting market competition for specific drugs.
Citations
[1] Bristol-Myers Squibb Company. (2023). United States Patent 11,566,011: Therapeutic compounds and methods of use. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
